A survey conducted by the National Comprehensive Cancer Network Best Practices Committee found that 93% of United States cancer centers polled in the report are experiencing a shortage of carboplatin, and 70% currently have a shortage of cisplatin.
The Biden administration has outsourced production of cancer drugs to a Chinese pharmaceutical giant that was once investigated for using a toxic sludge called gutter oil to make antibiotics.